The Effect of Metformin on the Incidence of Type 2 Diabetes Mellitus and Cardiovascular Disease Risk Factors in Overweight and Obese Subjects The Carmos Study
The Effect of Metformin on the Incidence of Type 2 Diabetes Mellitus and Cardiovascular Disease Risk Factors in Overweight and Obese Subjects The Carmos Study
复制标题
DOI：
10.1055/s-0028-1087177
复制
发表时间：
2009-04-01
影响因子：
1.8
通讯作者：
Diamantopoulos, E. J.
中科院分区：
文献类型：
--
作者：
Andreadis, E. A.;Katsanou, P. M.;Diamantopoulos, E. J.
We investigated whether the addition of metformin to the treatment of Overweight and obese individuals further reduces the incidence of type 2 diabetes mellitus (T2DM), prediabetes and metabolic syndrome (MetS) and improves Cardiovascular disease (CVD) risk factors (RFs).Design and methods: We studied 366 adults (mean age 53.0 +/- 0.5 SE years, and mean BMI 32.3 +/- 0.2 SE Kg/m(2)) Without CVD. All Subjects received lifestyle recommendations and drug management of CVD-RFs, whilst 95 of them were additionally given metformin. The follow-up period lasted 12 months.Results: At the end Of the Study the frequency of T2DM in the metformin and non-metformin group Was 1.1 and 8.1%, respectively (risk difference = -7% with 95% CI from -12.7% to -1.4%, p=0.012). Participants with prediabetes displayed a greater reduction in the incidence of T2DM after taking metformin compared to those who had not received this drug (risk difference = -18.5% with 95%CI from -33.1% to -3.9%, p=0.010). Metformin had a similar beneficial impact on Subjects with MetS (risk difference = -12.9% with 95% from -25% to -0.7%, p=0.040) and this was attributed to the greater increase in HDL-C (p=0.046) and decrease in fasting plasma glucose levels (p=0.024). Metformin also achieved a greater reduction in total cholesterol and LDL-C levels (metformin vs. non-metformin treated subjects: -31.9 vs. -17.3 mg/dl, p=0.001, and -26.2 vs. -15.9 mg/dl, p=0.006. respectively).Conclusions: Metformin reduces the occurrence of T2DM in Overweight and obese non-diabetic adults and decreases the rate of MetS by improving the CVD risk factor profile.
